Privately-held Belgian biotech firm Rewind Therapeutics has appointed Ian Reynolds as its chief executive.
Mr Reynolds is a leading neuro-pharmacologist and brings over 20 years of drug discovery and development experience with his career spanning academia, start-up enterprises in neuroscience drug discovery and big pharmaceutical companies, where he led large drug discovery and development teams and global licensing and collaboration initiatives. He worked on the discovery and development of novel therapeutics for Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s disease, multiple sclerosis and age-related macular degeneration.
Mr Reynolds is a member of the Innovative Medicines Initiative Strategic Governance Group on Neurodegeneration and of the Scientific Advisory Boards of the Michael J Fox Foundation, Target ALS and the Parkinson’s Foundation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze